GENinCode Reports 25% Revenue Growth and Narrows Losses in FY24

A Solid Step Forward for GENinCode

GENinCode’s latest results reveal a company hitting its stride. With revenue climbing 25% to £2.7m and losses narrowing significantly, this isn’t just incremental progress – it’s a meaningful acceleration. The predictive genetics specialist is translating scientific innovation into commercial momentum, particularly impressive given the macroeconomic headwinds many AIM-listed life science firms face.

The Growth Engine: Where’s the Traction Coming From?

Digging beneath the headline numbers reveals a geographically diversified expansion:

• UK & European Dominance: Still the cash engine, driving the bulk of growth through NHS adoption of LIPID inCode® for familial hypercholesterolemia (FH) diagnosis and THROMBO inCode® sales in Spain. The North of England NHS processed over 2,300 FH tests, directly supporting the NHS Long Term Plan.
• US Beachhead Established: First revenues landed for both LIPID inCode® (FH diagnosis) and CARDIO inCode® (coronary artery disease risk). While still early days, securing over 20 institutional sites is no small feat. The inclusion of CARDIO inCode® in the 2025 CMS Clinical Lab Fee Schedule (median price ~$500) is a crucial step for future reimbursement.
• European Pipeline Firing: Catalonia (Spain) adopting CARDIO inCode® for primary care cardiovascular risk assessment (addressable market ~476k patients) and German collaboration with Uniklinikum Dresden signal scalable models beyond the UK.
• ROCA’s Rising Star: The NICE-recommended ovarian cancer surveillance test secured its first NHS adoption via UCL. Expansion into Switzerland and Austria in 2024, with Germany and Spain in sight, adds another growth vector.

Financial Fitness: Tightening the Belt While Scaling

The 25% revenue jump to £2.7m is commendable, but the real story is on the bottom line. GENinCode slashed its adjusted EBITDA loss by over a third to £4.4m (from £6.7m in FY23). This wasn’t magic; it was disciplined execution:

• Margin Magic: Gross profit margin surged to 53% (up from 47%), showing increased operational efficiency and pricing power as volumes grow.
• Cost Control: Administrative expenses fell sharply to £5.9m (FY23: £7.8m), reflecting reduced spend on launch prep and external advisory costs post-initial commercialisation phase.
• Cash Cushion: Year-end cash stood at £1.1m (down from £2.5m), but crucially, a £4.1m secondary placing completed post-period-end significantly de-risks the near-term funding picture. The current £1.1m position underscores the necessity of that raise.

The FDA Factor: The Sword of Damocles… or Golden Ticket?

Let’s address the elephant in the room: the ongoing “progressive discussions” with the FDA regarding the De Novo pathway for CARDIO inCode®. The Notice of Deficiencies received in April wasn’t ideal, but the tone from management is notably confident. Why does this matter so much?

• Market Explosion: FDA approval transforms CARDIO inCode® from a service offered through specific channels to a nationally marketable medical device (“kit format”). This unlocks the colossal $10.5bn Total Addressable Market (with a $4.5bn Serviceable Available Market) Matthew Walls cites.
• Reimbursement Key: While CMS inclusion is positive, widespread commercial payer coverage typically follows FDA green lights, making adoption by major US healthcare institutions and state systems far smoother.
• Validation Catalyst: Approval wouldn’t just be regulatory; it would be a powerful endorsement of the polygenic risk score approach, potentially accelerating adoption globally.

Management expects to “finalise discussions” and agree the pathway in 2025. This remains the single biggest potential value inflection point for the company.

Pathway to Profitability: Not Just Wishful Thinking

The stated aim of “moving towards breakeven” isn’t just boilerplate optimism. The foundations seem plausible:

• Runway Secured: The £4.1m placing buys crucial time. With FY24 operating cash outflow at £5.17m, this extends the runway well into 2025, overlaying the existing £1.1m.
• Growth Leverage: The 53% gross margin demonstrates the model’s potential scalability. Further volume increases, particularly from higher-margin US sales post-potential FDA approval, could rapidly improve unit economics.
• Cost Discipline Embedded: The significant reduction in admin costs shows a newfound operational rigour. Continued “tight control” is promised.
• Early FY25 Momentum: Consolidated revenues for the first four months of FY25 are reportedly 20% higher than the same period in 2024. This suggests the growth trajectory is sustained.

Risks & The Road Ahead: Eyes Wide Open

No investment is without risk, and GENinCode investors should stay alert to:

• FDA Overhang: Failure to secure a clear De Novo pathway, or significant delays, would be a major setback for US ambitions and sentiment.
• Cash Burn: Even with the placing, the path to self-sufficiency requires continued revenue acceleration. The going concern note explicitly mentions reliance on revenue growth forecasts and potential future fundraises if targets slip.
• NHS Rollout Pace: While the North England programme is successful, broader NHS adoption of CARDIO inCode® and further LIPID inCode® expansion across regions needs to materialise as planned.
• Competition: The polygenic risk score space is attracting increasing attention. Maintaining technological leadership and commercial agility is key.

Conclusion: Building Momentum, But Execution is Key

GENinCode’s FY24 results paint a picture of a company transitioning from heavy R&D investment towards commercial scale. The 25% revenue growth and sharply reduced losses are tangible evidence of progress. The NHS foothold is strengthening, European partnerships are bearing fruit, and the crucial US entry has begun, albeit awaiting the pivotal FDA decision.

The £4.1m placing alleviates immediate funding concerns, providing runway to execute the 2025 plan: drive revenue growth (especially in the US), achieve FDA approval for CARDIO inCode®, expand NHS and European programmes, and crucially, continue narrowing losses towards breakeven.

CEO Matthew Walls’ confidence about “moving the business towards breakeven” feels more grounded than many AIM promises. While the FDA remains the critical variable, GENinCode is demonstrably building commercial momentum. For investors in predictive health, this is one to watch closely – the next 12 months could be transformative.